Executive Summary : | Alzheimer's disease (AD) is a multifactorial neurodegenerative disorder with an expected number of 152 million people by 2050. A multi-target strategy is considered effective for designing new molecules to modulate AD's interconnected targets. A dual classical GSK-3β/epigenetic HDAC6 inhibitor is designed for synthesis and biological study. Preliminary in silico studies show promising properties, binding affinity, and toxicity profile. The proposed four multistep schemes will synthesize the molecules, with the aim of discovering lead molecules for AD treatment. This research area is limited to one international study and no report from India. |